<DOC>
	<DOCNO>NCT00527904</DOCNO>
	<brief_summary>This study use open-label design conduct approximately 60 site aim enroll total number 200 subject ensure least 100 subject 12 month exposure PN400 ( VIMOVO ) .</brief_summary>
	<brief_title>A 12-month , Phase 3 , Open-label , Multi-center Study Evaluate Long-term Safety PN400 ( VIMOVO )</brief_title>
	<detailed_description>PN400 propose treatment sign symptom osteoarthritis , rheumatoid arthritis ankylose spondylitis medical condition expect require daily NSAID therapy least 12 month patient risk develop NSAID-associated gastric ulcer . This study design provide long-term safety data PN400 order gain regulatory approval make PN400 available clinical use subject population .</detailed_description>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Inclusion Criteria A subject eligible inclusion study follow criterion apply : 1 . Male nonpregnant female subject history osteoarthritis , rheumatoid arthritis , ankylose spondylitis medical condition expect require daily NSAID therapy least 12 month : 1849 year age history document , uncomplicated gastric duodenal ulcer ( mucosal break least 3 mm diameter depth , without concurrent bleeding , clot perforation ) within past 5 year , 50 year age old ( These subject require history document , uncomplicated gastric duodenal ulcer within past 5 year ) . 2 . Female subject eligible participation study Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; Childbearing potential , negative pregnancy test Screening , least 1 follow apply agreed subject : Female sterilization sterilization male partner ; , Hormonal contraception oral route , implant , injectable , vaginal ring ; , Any intrauterine device publish data show low expected failure rate le 1 % per year ; , Double barrier method ( 2 physical barrier 1 physical barrier plus spermicide ) ; Any method publish data show low expected failure rate le 1 % per year 3 . Each subject require able willing provide write informed consent prior study procedure perform . Exclusion Criteria A subject eligible inclusion study 1 follow criterion apply : 1 . History hypersensitivity esomeprazole another PPI 2 . History allergic reaction intolerance NSAID ( include aspirin ) and/or history NSAIDinduced symptom asthma , rhinitis , and/or nasal polyp 3 . Participation study investigational treatment 4 week Screening 4 . Presence uncontrolled acute chronic medical illness , e.g. , GI disorder , hypertension , diabetes , thyroid disorder , depression and/or infection would endanger subject he/she participate study 5 . GI disorder surgery lead impaired drug absorption 6 . Evidence uncontrolled unstable cardio cerebrovascular disorder investigator 's opinion would endanger subject he/she participate study 7 . Schizophrenia bipolar disorder 8 . Use excluded concomitant medication 9 . A recent history ( past 3 month ) suggestive alcohol drug abuse dependence , include overuse/abuse narcotics management pain 10 . Serious blood coagulation disorder , include use systemic anticoagulant 11 . Positive test result Helicobacter pylorus Screening 12 . Baseline endoscopy show gastric duodenal ulcer least 3 mm diameter depth 13 . Screening laboratory value follow test &gt; 2 time upper limit normal : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 14 . Estimated creatinine clearance &lt; 50 mL/min 15 . Other note specifically , screen laboratory value clinically significant investigator 's opinion would endanger subject subject participate study 16 . History malignancy , treat untreated , within past 5 year , exception successfully treat basal cell squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>ankylose spondylisit</keyword>
	<keyword>NSAIDS</keyword>
</DOC>